Bridget Nzarubara, MBChB, MSc. Epidemiology

Regulatory Affairs Manager, IDRC


E-mail Address:  reachbridget@yahoo.com

 

Bridget Nzarubara

Professional Interests:
Provide strategic, tactical and operational support for working within set national guidelines and policies in a clinical research environment.

 

Current Main Activities:
Manages and directs the overall activities of the Regulatory Affairs office.

Responsible for ensuring that all research activities are in compliance with Good Clinical Practice (GCP) and guidelines set by national and international regulatory bodies.

Keeping up-to-date on regulations essential in regulatory affairs; changes in regulations can affect the clinical trials process and regulatory strategy.

Provides guidance to investigators on regulatory issues. Acts as a liaison between the research organization and regulatory bodies.

 

Education and Training:
London School of Hygiene and Tropical Medicine (LSHTM), Masters in Epidemiology (Msc), 2010

US-Africa partners in protection Training, Addressing Regulatory Challenges, Zambia, Lusaka, 2010

Training in conducting Research Responsibly, Nairobi, Kenya, 2010

Makerere University; Kampala, Uganda, MBchB, Bachelor of medicine and surgery undergraduate degree

 

Publications:

1. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassali A, Rosenthal PJ, and Kamya M. Comparative efficacy of Aminoquinoline-Antifolate combinations for the treatment of uncomplicated falciparum Malaria in Kampala, Uganda. Am . J. Trop. Med. Hyg, 68(2), 2003, pp.127-132


2. Staedke SG, Mpimbaza A, Kamya M, Nzarubara BK, Dorsey G, Rosenthal PJ. Combination treatments for uncomplicated falciparum Malaria in Kampala, Uganda; Randomised Clinical trial. Lancet 2004:364: 1950-57


3. Njama-Meya. D, Clark. TD, Nzarubara. B, Staedke. S, Kamya. M, Dorsey.G. Treatment of Malaria restricted to laboratory confirmed cases: a prospective cohort study in Ugandan Children. Malaria journal, 2007 6:7


4. Greenhouse B, Slater M, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Clark TD, Staedke SG, Kamya MR, Hubbard A, Rosenthal PJ, Dorsey G. Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis. 2009 Mar 1;199(5):758-65.


5. Clark TD, Greenhouse B, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Staedke SG, Seto E, Kamya MR, Rosenthal PJ, Dorsey G. Factors Determining the Heterogeneity of Malaria Incidence in Children in Kampala, Uganda. J Infect Dis. 2008 Aug 1;198(3):393-400.


6. Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, Maiteki-Sebuguzi C, Clark TD, Nzarubara B, Njama-Meya D, Mpimbaza A, Rosenthal PJ, Kamya MR, Wabwire-Mangen F, Dorsey G, Talisuna AO. Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J. 2008 Jun 11;7(1):107.


7. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, Nzarubara B, Talisuna AO, Kamya MR, Rosenthal PJ, Dorsey G, Staedke SG. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J. 2008 Jun 11;7(1):106.


8. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA. 2007 May 23;297(20):2210-9.


9. Njama-Meya D, Clark TD, Nzarubara B, Staedke S, Kamya MR, Dorsey G. Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children. Malar J. 2007 Jan 21;6:7.